COMPANY
GRAIL
GRAIL is developing a precision oncology portfolio and in 2023 launched a research-use-only targeted methylation platform with customizable machine learning algorithms. From company website Source · Oct 12, 2026
Since the raise (Oct 20, 2025): 14 of 14 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Software Engineer - Commercial - #4978 | Sunnyvale, CA | Oct 13, 2026 | Oct 14, 2026 |
| Inside Sales Representative #4961 | Sunnyvale, CA | Oct 8, 2026 | Oct 9, 2026 |
| Senior Process Engineer - Compliance #4968 | Durham, NC | Oct 7, 2026 | Oct 9, 2026 |
| Material Handling Coordinator III #4954, #4955 (Tue - Sat) (Sun - Thurs) 8:00am - 5:00pm | Durham, NC | Oct 1, 2026 | Oct 9, 2026 |
| Senior / Staff Data Integrity Engineer (Compliance) #4942 | Sunnyvale, CA | Sep 30, 2026 | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (14 open jobs at last check). source ↗
- Raise Private placement: $325M (total, as published), announced Oct 20, 2025. Source: SEC filing. source ↗ · Form D filed Nov 7, 2025 SEC Form D ↗
- Partnership Partnership / licensing announced Oct 16, 2025. Source: SEC filing. source ↗
- Trial start —: The Galleri® Community Research Program source ↗
- Trial start Not phased (device or behavioral study): Galleri® in the Medicare Population. source ↗
- Trial start Not phased (device or behavioral study): PATHFINDER 2: A Multi-Cancer Early Detection Study source ↗
- Trial start Not phased (device or behavioral study): Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial source ↗
- Trial start —: REFLECTION: A Clinical Practice Learning Program for Galleri® source ↗
- Trial start Not phased (device or behavioral study): Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice source ↗
- Trial start —: The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types source ↗
- Trial start —: The Circulating Cell-free Genome Atlas Study source ↗
Upcoming milestones
- 2030-09 (ESTIMATED) · Not phased · Galleri® in the Medicare Population. · NCT05673018
Open jobs 14
Funding
- Private placement: $325M (total, as published), announced Oct 20, 2025. Source: SEC filing. source ↗ · Form D filed Nov 7, 2025 SEC Form D ↗
- Partnership / licensing announced Oct 16, 2025. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 8
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05611632 | Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial | Not phased (device or behavioral study) | Active, not recruiting | Aug 31, 2021 | Jun 12, 2026 (actual) |
| NCT05673018 | Galleri® in the Medicare Population. | Not phased (device or behavioral study) | Recruiting | Jul 12, 2024 | 2030-09 (estimated) |
| NCT05155605 | PATHFINDER 2: A Multi-Cancer Early Detection Study | Not phased (device or behavioral study) | Active, not recruiting | Dec 8, 2021 | Feb 11, 2026 (actual) |
| NCT05205967 | REFLECTION: A Clinical Practice Learning Program for Galleri® | Not listed | Active, not recruiting | Aug 23, 2021 | Sep 30, 2025 (actual) |
| NCT03085888 | The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types | Not listed | Completed | Feb 28, 2017 | Jun 30, 2022 (actual) |
| NCT06603259 | The Galleri® Community Research Program | Not listed | Unknown status (ClinicalTrials.gov) | Aug 19, 2024 | 2025-12 (estimated) |
| NCT02889978 | The Circulating Cell-free Genome Atlas Study | Not listed | Unknown status (ClinicalTrials.gov) | Aug 4, 2016 | 2024-03 (estimated) |
| NCT04241796 | Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice | Not phased (device or behavioral study) | Completed | Dec 12, 2019 | Dec 1, 2021 (actual) |
Raises and investors new
- Raise Private raise (SEC Form D): $325.0M sold; issuer “GRAIL, Inc.”. Verified from the SEC filing. SEC filing ↗
Connect
See your connections at GRAIL on LinkedIn (search by name, results not checked)